Trial
NCT02756728
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
BioInvent International AB
Collaborators
—
Condition
Multiple Myeloma
Intervention
BI-505
Why stopped
Full clinical hold from FDA
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-12